오하이오의 자궁내막암 임상 시험
자궁내막암 관련 연구 49개가 오하이오 내 여러 지역에서 참여자를 모집하고 있습니다.
오하이오의 도시
공식 연구 텍스트(영어)
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Miami Valley Hospital South, Centerville
- Geauga Hospital, Chardon
- 외 8개
피험자 모집 중2상
18세 이상 · 여성 · 2026. 11. 12. 업데이트됨 · NCT05112601Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
- Cleveland Clinic Foundation, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
피험자 모집 중1상
18세 이상 · 여성 · 2026. 11. 12. 업데이트됨 · NCT05950464Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- OhioHealth O'Bleness Hospital, Athens
- UH Seidman Cancer Center at UH Avon Health Center, Avon
- UHHS-Chagrin Highlands Medical Center, Beachwood
- 외 41개
피험자 모집 중2상
전 연령 · 모든 성별 · 2026. 11. 12. 업데이트됨 · NCT05564377Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Geauga Hospital, Chardon
- Case Western Reserve University, Cleveland
- 외 4개
피험자 모집 중2상
18세 이상 · 여성 · 2026. 11. 12. 업데이트됨 · NCT05640999A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- Miami Valley Hospital South, Centerville
- Ohio State University, Hilliard
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 10. 업데이트됨 · NCT06340568A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
- Miami Valley Hospital South ( Site 6014), Centerville
- University of Cincinnati Medical Center ( Site 5013), Cincinnati
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007), Columbus
- 외 1개
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 10. 업데이트됨 · NCT06952504Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
- OhioHealth O'Bleness Hospital, Athens
- UHHS-Chagrin Highlands Medical Center, Beachwood
- Aultman Health Foundation, Canton
- 외 19개
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 6. 업데이트됨 · NCT07198074Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
- Cleveland Clinic Foundation, Cleveland
피험자 모집 중관찰 연구
18세 이상 · 여성 · 2026. 11. 5. 업데이트됨 · NCT05051722Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
- Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT05579366A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
- The Ohio State University (OSU) Wexner Medical Center, Columbus
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06400472A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Cleveland Clinic - Oncology Department, Cleveland
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06760819Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
- Gabrail Cancer & Research Center, Canton
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT05856981Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
- University of Cincinnati Medical Center, Cincinnati
피험자 모집 중3상
18세 이상 · 여성 · 2026. 11. 3. 업데이트됨 · NCT07166094Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
- Miami Valley Hospital South, Centerville
피험자 모집 중3상
18세 이상 · 여성 · 2026. 10. 30. 업데이트됨 · NCT07578649A Phase 1 Study of LNCB74 in Advanced Solid Tumors
- Cleveland Clinic Taussig Cancer Institute, Cleveland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 29. 업데이트됨 · NCT06774963A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- UH Cleveland Medical Center, Cleveland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT07109726A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant Setting
- University of Cincinnati Physicians Group, LLC, Cincinnati
피험자 모집 중3상
18세 이상 · 여성 · 2026. 10. 27. 업데이트됨 · NCT07022483A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
- Oncology Hematology Care Primary, Cincinnati
- Taylor Cancer Research Center, Maumee
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 22. 업데이트됨 · NCT04657068DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
- Research Site, Cincinnati
- Research Site, Columbus
피험자 모집 중3상
18세 이상 · 여성 · 2026. 10. 13. 업데이트됨 · NCT06989112Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
- The Ohio State University, Columbus
피험자 모집 중1상
15세 이상 · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT06276491FOG-001 in Locally Advanced or Metastatic Solid Tumors
- University Hospitals Cleveland Medical Center, Seidman Cancer Center, Cleveland
- Cleveland Clinic, Cleveland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 7. 업데이트됨 · NCT05919264Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
- Research Site, Columbus
피험자 모집 중1/2상
18세 ~ 130세 · 모든 성별 · 2026. 10. 5. 업데이트됨 · NCT05797168The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- The Cleveland Clinic Taussig Cancer Center, Cleveland
피험자 모집 중1/2상
12세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT04585750A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 06, Maumee
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 30. 업데이트됨 · NCT07814248Study of AVZO-021 in Patients With Advanced Solid Tumors
- Avenzo Therapeutics Recruiting Site, Cleveland
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT05867251Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
- The Ohio State University Wexner Medical Center, Columbus
피험자 모집 중1/2상
18세 이상 · 여성 · 2026. 9. 25. 업데이트됨 · NCT03564340DESTINY-PANTUMOUR04
- Research Site, Canton
- Research Site, Maumee
피험자 모집 중관찰 연구
18세 ~ 130세 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07124000A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- The Ohio State University Wexner Medical Center, Columbus
피험자 모집 중1/2상
18세 이상 · 여성 · 2026. 9. 24. 업데이트됨 · NCT04590326Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Cincinnati
- Research Site, Columbus
피험자 모집 중2상
18세 ~ 130세 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT05489211A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
- GSK Investigational Site, Canton
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT07213609ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cleveland Clinic, Cleveland
- Toledo Clinic Cancer Center, Toledo
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT05059444Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Cincinnati Children's Hospital Medical Center, Cincinnati
피험자 모집 중1/2상
12 Months – 30 Years · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT04851119A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
- Miami Valley Hospital South, Centerville
- University of Cincinnati Cancer Center, Cincinnati
- Ohio State University, Hilliard
피험자 모집 중2상
18세 이상 · 여성 · 2026. 8. 21. 업데이트됨 · NCT05548296A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Maumee
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT07182149A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
- Ohio State University Wexner Medical Center, Columbus
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 18. 업데이트됨 · NCT07470853A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- The Ohio State University Comprehensive Cancer Center, Columbus
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 11. 업데이트됨 · NCT05592626Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
- University Hospital - Cleveland Medical Center, Cleveland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 5. 업데이트됨 · NCT07444814Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Cincinnati
- Research Site, Cleveland
- Research Site, Cleveland
- 외 4개
피험자 모집 중3상
18세 이상 · 여성 · 2026. 7. 29. 업데이트됨 · NCT07044336A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- University Hospitals Cleveland Medical Center, Cleveland
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 7. 22. 업데이트됨 · NCT05208762Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
- 304, Centerville
피험자 모집 중2상
18세 이상 · 여성 · 2026. 7. 16. 업데이트됨 · NCT06906341ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.